Trial
NCT01150890
Brodalumab (AMG 827) in Adults With Moderate to Severe Crohn's Disease
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Amgen
Collaborators
—
Condition
Crohn's Disease
Intervention
Brodalumab
Why stopped
The study was terminated early based on an imbalance in worsening Crohn's disease in active treatment groups
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-01-03